Nanocarry Therapeutics

Company Overview

Snapshot

Founded in January 2021 by Revital Mandil Levin, Rachela Popovtzer, and Oshra Betzer, Nanocarry Therapeutics operates with 11–50 employees. The company has raised $1M across four funding rounds from three investors. In January 2025, NFX Capital led a Seed funding round.

Business overview

Nanocarry Therapeutics develops bioengineered nanoparticle-based therapeutics designed to treat oncology indications and brain diseases. The company's core AxS platform is engineered for versatile delivery of biologics to the brain and other areas. Nanocarry's initial product pipeline focuses on addressing brain metastases associated with HER2+ breast cancer and non-small cell lung cancer, operating within the Health Tech & Life Sciences sector.

Company Intelligence Q&A

What is Nanocarry Therapeutics' primary focus?

Nanocarry Therapeutics focuses on developing nanoparticle-based therapeutics for brain cancer and central nervous system disorders, utilizing its AxS platform for targeted biologic delivery.

When was Nanocarry Therapeutics founded and by whom?

Nanocarry Therapeutics was founded in January 2021 by co-founders Revital Mandil Levin, Rachela Popovtzer, and Oshra Betzer.

Which investors participated in Nanocarry Therapeutics' Seed funding round in January 2025?

In January 2025, Nanocarry Therapeutics secured Seed funding led by.

Did Nanocarry Therapeutics receive any grants recently?

In January 2024, Nanocarry Therapeutics received a grant from the Israel Innovation Authority.

Which investors participated in Nanocarry Therapeutics' funding round in August 2024?

In August 2024, Nanocarry Therapeutics received funding from Sapir Venture Partners.